The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models

References

• Galliverti G, Wullschleger S, Tichet M, et al. Myeloid cells orchestrate systemic immunosuppression, impairing the efficacy of immunotherapy against HPV+ cancers. Cancer Immunol Res. 2020;8(1):131–145. doi:10.1158/2326-6066.CIR-19-031531771984
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. doi:10.1126/scitranslmed.3002842
   PubMed Web of Science ®Google Scholar
• Fife BT, Pauken KE, Eagar TN, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10(11):1185–1192. doi:10.1038/ni.179019783989
   PubMed Web of Science ®Google Scholar
• Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21(9):1065–1077. doi:10.1093/intimm/dxp07219651643
   PubMed Web of Science ®Google Scholar
• Robertson SA, Care AS, Moldenhauer LM. Regulatory T cells in embryo implantation and the immune response to pregnancy. J Clin Invest. 2018;128(10):4224–4235. doi:10.1172/JCI12218230272581
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.0056128878676
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PDL1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567. doi:10.1038/nature1401125428504
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi:10.1038/s41577-20-0306-532433532
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562. doi:10.1038/nature1390425428503
   PubMed Web of Science ®Google Scholar
• Bour-Jordan H, Esensten JH, Martinez-Llordella M, et al. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/B7 family. Immunol Rev. 2011;241(1):180–205. doi:10.1111/j.1600-065X.2011.01011.x21488898
   PubMed Web of Science ®Google Scholar
• Ware CF. The TNF receptor super family in immune regulation. Immunol Rev. 2011;244(1):5–8. doi:10.1111/j.1600-065X.2011.01065.x22017427
   PubMed Web of Science ®Google Scholar
• Ellis GI, Sheppard NC, Riley JL. Genetic engineering of T cells for immunotherapy. Nat Rev Genet. 2021;22(7):427–447. doi:10.1038/s41576-021-00329-933603158
   PubMed Web of Science ®Google Scholar
• Duewell P, Steger A, Lohr H, et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells. Cell Death Differ. 2014;21(12):1825–1837. doi:10.1038/cdd.2014.9625012502
   PubMed Web of Science ®Google Scholar
• Zhu YQ, Zheng Y, Mei L, et al. Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus. Int J Oncol. 2013;43(4):1151–1159. doi:10.3892/ijo.2013.202723877655
   PubMed Web of Science ®Google Scholar
• Zheng Y, Hu B, Xie S, et al. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models. Cytotherapy. 2017;19(5):617–628. doi:10.1016/j.jcyt.2017.01.00828215653
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Ito M, Chikuma S, Akanuma T, Nakatsukasa H. Negative regulation of cytokine signaling in immunity. Cold Spring HarbPerspect Biol. 2018;10(7):a028571. doi:10.1101/cshperspect.a028571
   PubMed Web of Science ®Google Scholar
• Hanada T, Yoshida H, Kato S, et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity. 2003;19(3):437–450. doi:10.1016/S1074-7613(03)00240-114499118
   PubMed Web of Science ®Google Scholar
• Tang X, Li Q, Zhu Y, et al. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy. Am J Transl Res. 2015;7(3):460–473. eCollection 201526045887
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733. doi:10.1056/NEJMoa110384921830940
   PubMed Web of Science ®Google Scholar
• DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for osteosarcoma: into the roaring 2020s. Adv Exp Med Biol. 2020;1257:109–131. doi:10.1007/978-3-030-43032-0_1032483735
   PubMed Web of Science ®Google Scholar
• Holstein SA, Lunning MA. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin Pharmacol Ther. 2020;107(1):112–122. doi:10.1002/cpt.167431622496
   PubMed Web of Science ®Google Scholar
• Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471–482. doi:10.1016/j.ccell.2019.09.00631715131
   PubMed Web of Science ®Google Scholar
• Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep. 2014;47(3):122–129. doi:10.5483/bmbrep.2014.47.3.28324499671
   PubMed Web of Science ®Google Scholar
• Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG. Continuous 4-1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology. 2013;2(9):e25581. doi:10.4161/onci.2558124319633
   PubMed Web of Science ®Google Scholar
• Voo KS, Bover L, Harline ML, et al. Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function. J Immunol. 2013;191(7):3641–3650. doi:10.4049/jimmunol.120275224014877
   PubMed Web of Science ®Google Scholar
• Habibagahi M, Razmkhah M, Niri NM, Hosseini A, Ghaderi A, Jaberipour M. Combined 4-1BB and CD28 costimulation could unleash lymphocytes from immunosuppression induced by adipose derived stem cell soluble products. Immunol Invest. 2013;42(4):307–323. doi:10.3109/08820139.2013.76431523883199
   PubMed Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144. doi:10.1172/JCI8309227454297
   PubMed Web of Science ®Google Scholar
• Reynolds J, Sando GS, Marsh OB, et al. Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 2012;27(4):1343–1350. doi:10.1093/ndt/gfr52921965585
   PubMed Web of Science ®Google Scholar
• Eikawa S, Mizukami S, Udono H. Monitoring multifunctionality of immune-exhausted CD8 T cells in cancer patients. Methods Mol Biol. 2014;1142:11–17. doi:10.1007/978-1-4939-0404-4_224706270
   PubMedGoogle Scholar
• Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017;11(4):554–562. doi:10.1007/s11684-017-0543-628625015
   PubMed Web of Science ®Google Scholar
• Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23(9):2255–2266. doi:10.1158/1078-0432.CCR-16-130027815355
   PubMed Web of Science ®Google Scholar
• Tanoue K, Shaw AR, Watanabe N, et al. Armed oncolytic adenovirus–expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T cells in solid tumors. Cancer Res. 2017;77(8):2024–2051. doi:10.1158/0008-5472.CAN-16-1577
   Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J ImmunoTher Cancer. 2019;7(1):304. doi:10.1186/s40425-019-0806-731727131
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–856. doi:10.1038/nbt.419530102295
   PubMed Web of Science ®Google Scholar
• Karim R, Jordanova ES, Piersma SJ, et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009;15(20):6341–6347. doi:10.1158/1078-0432.CCR-09-165219825956
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Ayada T, Kinjyo I, et al. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci. 2009;100(4):730–736. doi:10.1111/j.1349-7006.2009.01098.x19469017
   PubMed Web of Science ®Google Scholar